Investigation Report on China’s Tigecycline Markets, 2016-2020 & 2021-2025: A Broad-spectrum Glycyl Cyclic Peptide Antibiotic Administered Intravenously – ResearchAndMarkets.com


DUBLIN–(BUSINESS WIRE)–The “Investigation Report on China’s Tigecycline Market 2021-2025” report has been added to ResearchAndMarkets.com’s offering.

logo

Tigecycline is a broad-spectrum glycyl cyclic peptide antibiotic administered intravenously. Tigecycline is approved for complicated skin and skin structure infections or complicated intra-abdominal infections patients aged 18 and over.

These infections include complicated appendicitis, burn infection, intra-abdominal abscess, deep soft tissue infection and ulcer infection.

Tigecycline was developed by Wyeth Corporation of the United States and was listed in China under the trade name TYGACIL in 2011. Subsequently, some generic drugs from local Chinese companies were listed. By 2020, tigecycline has been included in China’s Class B medical insurance, and there are several manufacturers in the Chinese tigecycline market.

According to the market research, the sales value of tigecycline in the Chinese market increased year by year at a compound annual growth rate of 43.45% from 2016 to 2019.

Due to the impact of COVID-19 on the overall diagnosis and treatment services of Chinese hospitals, the sales value of tigecycline in the Chinese market decreased to CNY 885 million in 2020 and the CAGR of tigecycline sales value from 2016 to 2020 is 28.64%.

The analyst expects that the sales value of tigecycline in the Chinese market will have a restorative growth from 2016 to 2020 with the relief of COVID-19. According to the latest set of data disclosed by the World Health Organization, 700,000 people worldwide die each year due to “super bacteria” infection, and 230,000 newborns die prematurely because of this.

It can be estimated that by 2050, the number of deaths may exceed 10 million. Therefore, the sales value and sales volume of tigecycline against “super bacteria” such as methicillin-resistant Staphylococcus aureus (MRSA) will continue to rise.

By the first half of 2021, the new indication for tigecycline in the Chinese market-community and hospital-acquired pneumonia is under review. It can be expected that with the increase in new indications in the future, the sales value and sales volume of tigecycline have room to rise.

Topics Covered:

  • The impact of COVID-19 on China’s Tigecycline market
  • Sales value of China’s Tigecycline 2016-2020
  • Competitive landscape of China’s Tigecycline market
  • Prices of Tigecycline in China
  • Prices of Tigecycline in China by regions and manufacturers
  • Analysis on factors affecting the development of China’s Tigecycline market
  • Prospect of China’s Tigecycline market from 2021 to 2025

Key Topics Covered:

1 Relevant Concepts of Tigecycline

1.1 Indications for Tigecycline

1.2 Development of Tigecycline in China

1.3 Governmental Approval of Tigecycline in China

1.4 The Impact of COVID-19 on Tigecycline sales in China

2 Sales of Tigecycline in China, 2016-2020

2.1 Sales Value of Tigecycline

2.1.1 Overall Sales Value

2.1.2 Sales Value by Region

2.2 Sales Volume of Tigecycline

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Region

2.3 Sales of Tigecycline by Dosage Form in China, 2016-2020

2.3.1 Injection

2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Tigecycline Manufacturers in China, 2016-2020

3.1 Analysis of Market Share of Major Tigecycline Manufacturers

3.1.1 Investigation on Market Share by Sales Value

3.1.2 Investigation on Market Share by Sales volume

3.2 Pfizer Ltd

3.2.1 Enterprise Profile

3.2.2 Sales of TYGACIL (Pfizer Ltd’s Tigecycline) in China

3.3 Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

3.3.1 Enterprise Profile

3.3.2 Sales of Zhetan (Jiangsu Hansoh Pharmaceutical Group Co., Ltd.’s Tigecycline) in China

3.4 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

3.4.1 Enterprise Profile

3.4.2 Sales of Tianjie (Chia Tai Tianqing Pharmaceutical Group Co., Ltd.’s Tigecycline) in China

3.5 Zhejiang Hisun Pharmaceutical Co., Ltd.

3.5.1 Enterprise Profile

3.5.2 Sales of Hisun Liliang (Zhejiang Hisun Pharmaceutical Co., Ltd.’s Tigecycline) in China

3.6 Jiangsu Osaikang Pharmaceutical Co., Ltd.

3.6.1 Enterprise Profile

3.6.2 Sales of Aotijia (Jiangsu Osaikang Pharmaceutical Co., Ltd.’s Tigecycline) in China

4 Prices of Tigecycline for Different Manufacturers in China, 2020-2021

4.1 Pfizer Ltd (TYGACIL)

4.2 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (Zhetan)

4.3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Tianjie)

4.4 Zhejiang Hisun Pharmaceutical Co., Ltd. (Hisun Liliang)

4.5 Jiangsu Osaikang Pharmaceutical Co., Ltd. (Aotijia)

5 Prospect of Chinese Tigecycline drug Market, 2021-2025

5.1 Influential Factors of Chinese Tigecycline Market Development

5.1.1 The Impact of COVID-19 on Chinese Tigecycline Market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Forecast on Market Size

5.3 Forecast on Market Trend

Companies Mentioned

  • Pfizer Ltd (TYGACIL)
  • Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (Zhetan)
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Tianjie)
  • Zhejiang Hisun Pharmaceutical Co., Ltd. (Hisun Liliang)
  • Jiangsu Osaikang Pharmaceutical Co., Ltd. (Aotijia) 

For more information about this report visit https://www.researchandmarkets.com/r/6fb5l2

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



Source link

The content is by Business Wire. Headlines of Today Media is not responsible for the content provided or any links related to this content. Headlines of Today Media is not responsible for the correctness, topicality or the quality of the content.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy